Disease Markers / 2019 / Article / Tab 1

Research Article

sFlt-1/PlGF Ratio as a Predictive Marker in Women with Suspected Preeclampsia: An Economic Evaluation from a Swiss Perspective

Table 1

Treatment scenario and services provided for the outpatient setting (low and intermediate follow-up).

ServiceInitial consultation (all patients)Outpatient management
Low follow-upIntermediate follow-up

Duration8 weeks8 weeks
Consultation1xEvery 7-10 days (6x)Weekly (8x)
Blood pressure measurement1xEvery 7-10 days (6x)Weekly (8x)
Blood analyses (ALAT/GPT, ASAT/GOT, LDH, haptoglobin, creatinine)1xWeekly (8x)
Fetal ultrasound with Doppler/CTG1xEvery 7-10 days (6x)Weekly (8x)
Proteinuria (quantitative)1x
Proteinuria (fast strip)Every 7-10 days (6x)Weekly (8x)
sFlt-1/PlGF ratio1x
Costs per week (€)531200547

Based on the assumption that a proportion of women would be hospitalized after 4 weeks. ALAT/GPT: alanine aminotransferase; ASAT/GOT: aspartate aminotransferase; CTG: cardiotocography; LDH: lactate dehydrogenase; PlGF: placental growth factor; sFlt-1: soluble fms-like tyrosine kinase-1.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.